Clinical trial
ADI-PEG in Patients With Metastatic Melanoma
NCT00029900 · FDA Office of Orphan Products Development, U.S. Fed · Completed
Key facts
| NCT number | NCT00029900 |
|---|---|
| Title | ADI-PEG in Patients With Metastatic Melanoma |
| Official title | Phase I Testing of ADI-PEG in Metastatic Melanoma |
| Lead sponsor | FDA Office of Orphan Products Development, U.S. Fed |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | ADI PEG |
| Enrollment | 15 |
| Start date | Sep 1, 2001 |
| Completion | Aug 1, 2003 |
| First posted | Jan 25, 2002 |
| Last update posted | Mar 25, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: